Pulike Bio obtains new veterinary drug registration certificate

Pulike Biological Engineering (SSE:603566) announced that it has received a new veterinary drug registration certificate for its "Chicken Newcastle Disease, Avian Influenza (H9 subtype), Infectious Bursal Disease, Avian Adenovirus Disease (Group I, Type 4) Quadrivalent Inactivated Vaccine". The vaccine, developed jointly with Luoyang Huizhong Biotechnology, targets several major diseases affecting poultry. The company has invested CNY 1,394.77 million in the research and development of this product to date. This new vaccine is expected to simplify immunization procedures, reduce stress on poultry, and enhance Pulike's product competitiveness, potentially driving future revenue growth. While the company has received the registration certificate, they are still awaiting final marketing approval.